Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | CASP3 | P42574 | 4/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14338224 | 0.82 | HPSE (0.49) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL507169 | 0.80 | KDM4E (0.77) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5406486 | 0.80 | HPSE (0.49) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5406479 | 0.80 | HPSE (0.49) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5395595 | 0.79 | HPSE (0.57) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5398947 | 0.79 | HPSE (0.57) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27733001 | 0.79 | CYP3A4 (0.47) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1736296 | 0.79 | CETP (0.81) | TP53MAPT | |
| SCHEMBL14338225 | 0.78 | SMN1; SMN2 (0.60) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10289630 | 0.78 | SMN1; SMN2 (0.74) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312230-B2 | Carboxylic acid derivatives as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312230-B2 | Carboxylic acid derivatives as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312230-B2 | Carboxylic acid derivatives as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7056903-B2 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | COURNOYER RICHARD L | 2006-02-16 | — | — | US | disclosed |
| US-6693098-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIVES CONTAINING CARBAMATE GROUPS ARE USEFUL FOR TREATING THE CONDITIONS ASSOCIATED WITH THE URINARY TRACT, PAIN, INFLAMMATION, RESPIRATORY STATES, EDEMA FORMATION OF HYPOTENSIVE VASCULAR DISEASES | SYNTEX (U.S.A) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | COURNOYER RICHARD LEO (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1265853-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2002-12-18 | — | — | EP | disclosed |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2001-12-27 | — | — | US | disclosed |
| WO-2001068591-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | AGTR1, AGTR2, PTGIR | KDM4E 4329/4885NPC1 3982/4885RAB9A 2922/4885 |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | KDM4E 4477/4885NPC1 1848/4885RAB9A 1955/4885 |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | KDM4E 4538/4885NPC1 1903/4885RAB9A 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.